Rose Meltzer uses her background as a writer and knowledge of health policy to research and analyze a variety of topics for clients.

Her primary interests are federal and state policies around the Affordable Care Act and Medicaid.  

Before joining Avalere, Rose covered payer and health IT news for FierceHealthcare. She reported on congressional hearings, attended press briefings, tracked legislation, and interviewed experts. Prior to that, she worked with Deloitte's Center for Health Solutions, studying and writing about health policy, financing, and administration. She also interned with the Public Health Law and Policy Program at the Centers for Disease Control and Prevention.

Rose has an MPH from the George Washington University and a BA from Arizona State University.

Authored Content


Health plans, including Medicare prescription drug plans, commonly apply utilization management (UM) tools to manage spending on prescription drugs.

Recent regulatory changes have eased restrictions for providers delivering care across state lines during the COVID-19 public health emergency. However, state and federal cooperation on extended licensure expansion would help address long-term provider access issues.

As plans continue to assess the proposed changes to their liability in the Medicare Part D benefit, understanding variations in spending by enrollee can help elucidate how policy changes might affect their spending. This Avalere analysis examines a subset of MA-PD and PDP plans with at least 75% of their enrollment comprising those with LIS. This analysis aims to quantify spending on drugs within the 6 protected classes for low-income subsidy (LIS) and non-LIS beneficiaries in this subset of PDP and MA-PD plans.

According to a new analysis from Avalere, Medicare Part D plans place generic prescription drugs on non-generic tiers 53% of the time in 2020.

New analysis from Avalere finds 52% of Part D plans achieve generic substitution1 rates above 75%.

Avalere analysis finds that payment to Medicare Advantage (MA) plans for end-stage renal disease (ESRD) patients in highly populated regions may be significantly below actual patient costs.